GENETIC INFLUENCES ON RESPONSE TO DRUG TREATMENT FOR MAJOR PSYCHIATRIC DISORDERS

GENETIC INFLUENCES ON RESPONSE TO DRUG TREATMENT FOR MAJOR PSYCHIATRIC DISORDERS

Editorial:
SPRINGER
Año de edición:
Materia
Farmacia
ISBN:
978-3-319-27038-8
Páginas:
117
N. de edición:
1
Idioma:
Inglés
Disponibilidad:
Disponible en 2-3 semanas

Descuento:

-5%

Antes:

77,99 €

Despues:

74,09 €

1. Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia.
2. Pharmacogenetics of Serious Antipsychotic Side-Effects.
3. Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs.
4. Genomic Studies of Treatment Resistance in Major Depressive Disorders.
5.Complementation of Pharmacogenetics with Biomarkers and Neuroimaging in Major Depression.
6. Pharmacogenetics of Mood Stabilizers.
7. Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant and Mood-Stabilizing Drugs.

Written by global experts, this book provides a modern comprehensive insight into the pharmacogenetics of treatment of major psychoses: schizophrenia, bipolar disorder and depression. The pharmacogenomics of three categories of the most important psychiatric drugs, antipsychotics, antidepressants and mood stabilizers, has been updated and reviewed.
Some promising directions and perspectives for future research in pharmacogenetics in major psychoses are indicated. They are, among others, connected with the development of new methods in molecular genetics and with linking pharmacogenetics assessment with biomarkers, including neuroimaging ones. Finally, the attempts to use pharmacogenetics of antipsychotic, antidepressant and mood-stabilizing drugs in practice are presented. New pharmacogenetic tools may greatly contribute to introducing personalized medicine into psychiatric clinical practice.

Features
• Updated comprehensive review of the pharmacogenetics of treatment of major psychoses: schizophrenia, bipolar disorder and depression
• Modern pharmacogenomics of the most important psychotropic drugs such as antipsychotics, antidepressants and mood stabilizers
• The attempts to use pharmacogenetics of antipsychotics, antidepressant and mood-stabilizing drugs in practice
• Perspectives for future research in pharmacogenetics in major psychoses

Author
Prof. Janusz K. Rybakowski has been the Head of Department of Adult Psychiatry, Poznan University of Medical Sciences, Poland, since 1994. He has authored over 500 scientific articles and book chapters on clinical psychiatry, neurobiology and psychopharmacology and his present Hirsch Index is 40. He is the author of the book “The Faces of Manic-Depressive Illness” (2009) and a member of many scientific societies including ECNP, CINP, Society of Biological Psychiatry, International Society of Psychiatric Genetics, International Society of Affective Disorders and International Society of Bipolar Disorders. He serves on editorial boards of numerous international journals and is the Field Editor of the World Journal of Biological Psychiatry. From 1998-2001 he was the President of the Polish Psychiatric Association. In 2012, he received the Lifetime Achievement Award of the European Bipolar Forum and in 2015, the Lifetime Achievement Award in Biological Psychiatry.